Does liquid clonazepam help burning mouth syndrome ?

Liquid clonazepam has been used in the management of burning mouth syndrome (BMS), showing some efficacy particularly in reducing symptoms over time, but it is not definitively superior to other treatments such as topical liquid N-acetylcysteine or combination therapies. Patients treated with oral clonazepam exhibited significant symptom improvement from week 4 to week 8, although the magnitude of symptom change did not significantly differ from those treated with topical liquid N-acetylcysteine alone or in combination with clonazepam Kim et al. 2025. Importantly, while clonazepam monotherapy reduced pain scores gradually, combination therapy with liquid N-acetylcysteine led to a faster improvement in patient-reported oral health-related quality of life, though differences among groups were not sustained at 8 weeks Kim et al. 2025.

From a UK guideline perspective, clonazepam is recognized as one of several pharmacologic options consistent with neuropathic pain management practices for BMS, reflecting its potential utility, especially when conventional measures fail NICE CG173. However, BMS remains a challenging condition with limited definitive treatments NICE CG173.

Recent evidence also highlights that treatment-resistant BMS frequently coexists with neuropsychiatric comorbidities, especially adult ADHD, which can significantly impact symptom severity and treatment responsiveness Takahashi et al. 2025. In such refractory cases, ADHD-targeted pharmacotherapy, including agents modulating dopaminergic and noradrenergic pathways, may provide substantial symptom relief, addressing both pain and associated cognitive or emotional dysfunction Takahashi et al. 2025. This suggests that while clonazepam may offer symptomatic benefit, comprehensive multidisciplinary assessment and treatment, including psychiatric evaluation, are crucial for optimal management of BMS.